Bank of America has revised its price target for Waters Corporation (WAT, Financial), reducing it from $410 to $350 while maintaining a Neutral rating on the stock. The adjustment comes as sentiment turns increasingly cautious regarding companies in the Life Sciences and Diagnostic Tools sector, as well as Contract Research Organizations.
The industry is currently grappling with a range of policy challenges originating from previous U.S. administration changes. These include potential impacts from National Institutes of Health (NIH) budget cuts and international tariffs. Additionally, there are broader macroeconomic concerns, particularly those related to the Chinese market, which are adding to the uncertainty faced by these companies as they approach their earnings season.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 19 analysts, the average target price for Waters Corp (WAT, Financial) is $403.35 with a high estimate of $460.00 and a low estimate of $343.11. The average target implies an upside of 22.23% from the current price of $330.01. More detailed estimate data can be found on the Waters Corp (WAT) Forecast page.
Based on the consensus recommendation from 23 brokerage firms, Waters Corp's (WAT, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Waters Corp (WAT, Financial) in one year is $348.46, suggesting a upside of 5.59% from the current price of $330.01. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Waters Corp (WAT) Summary page.
